Abstract:Cervical cancer remains the second-most prevalent female malignancy around the world, leading to a great majority of cancer-related mortality that occurs mainly in developing countries. Developing an effective and low-cost vaccine against human papillomavirus (HPV) infection, especially in medically underfunded areas, is urgent. Compared with vaccines based on HPV L1 viruslike particles (VLPs) in the market, recombinant HPV L1 pentamer expressed in Escherichia coli represents a promising and potentially cost-effective vaccine for preventing HPV infection. Hybrid particles comprising a polymer core and lipid shell have shown great potential compared to conventional aluminum salts adjuvant and is urgently needed for HPV L1 pentamer vaccines. It is well-reported that particle sizes are crucial in regulating immune responses. Nevertheless, reports on the relationship between the particulate size and the resultant immune response have been in conflict, and there is no answer to how the size of particles regulates specific immune response for HPV L1 pentamer-based candidate vaccines. Here, we fabricated HPV 16 L1 pentamer-loaded poly(d,l-lactide- co-glycolide) (PLGA)/lecithin hybrid particles with uniform sizes (0.3, 1, and 3 μm) and investigated the particle size effects on antigen release, activation of lymphocytes, dendritic cells (DCs) activation and maturation, follicular helper CD4+ T (TFH) cells differentiation, and release of pro-inflammatory cytokines and chemokines. Compared with the other particle sizes, 1 μm particles induced more powerful antibody protection and yielded more persistent antibody responses, as well as more heightened anamnestic responses upon repeat vaccination. The superior immune responses might be attributed to sustainable antigen release and robust antigen uptake and transport and then further promoted a series of cascade reactions, including enhanced DCs maturation, increased lymphocytes activation, and augmented TFH cells differentiation in draining lymph nodes (DLNs). Here, a powerful and economical platform for HPV vaccine and a comprehensive understanding of particle size effect on immune responses for HPV L1 pentamer-based candidate vaccines are provided.

Trivalent Human Papillomavirus (hpv) Vlp Vaccine Covering Hpv Type 58 Can Elicit High Level of Humoral Immunity but Also Induce Immune Interference among Component Types

A single-injection vaccine providing protection against two HPV types

Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59

A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26

Expression of Genetically Modified Human Papillomavirus Type 58 L1 Gene and Production of Antisera Against Resultant VLP

A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses.

Induction of Cross-Neutralizing Antibodies by Sequential Immunization with Heterologous Papillomavirus L1VLPs and Its Implications for HPV Prophylactic Vaccines.

Stability of trivalent human papillomavirus (types 16, 18, 58) recombinant vaccine (Escherichia coli)

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model

Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles

Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14‐valent recombinant human papillomavirus vaccine

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates

Human Papillomavirus L1 Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles That Are Highly Immunogenic.

Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)

N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro

Recombinant Virus-like Particles of Human Parvovirus B19 with the Internal Location of VP1 Unique Region Produced by Hansenula polymorpha

Safety and immunogenicity of a pichia pastoris -expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial

Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibody

Enhanced Broad-Spectrum Efficacy of an L2-Based mRNA Vaccine Targeting HPV Types 6, 11, 16, 18, with Cross-Protection Against Multiple Additional High-Risk Types